Heart Failure Pipeline Drugs and Development, Companies Insight Report (2022) : Analysis of Clinical Trials, Therapies, Mechanism of Action, and Route of Administration

October 19 16:21 2022
Heart Failure Pipeline Drugs and Development, Companies Insight Report (2022) : Analysis of Clinical Trials, Therapies, Mechanism of Action, and Route of Administration
Heart Failure pipeline constitutes 90+ key companies continuously working towards developing 90+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Heart Failure Overview

Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations.

 

Heart Failure Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market. 

 

The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Heart Failure Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years. Heart Failure Key players such as – GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Asklepios Biopharmaceutical, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment 
  • Heart Failure Emerging therapies such as – GSK3884464, LY 3461767, JK07, NAN-101, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.  
  • In June 2019, The Food and Drug Administration (FDA) granted Orphan Drug designation to Revascor (rexlemestrocel-L; Mesoblast), a potential therapy for the prevention of post-implantation mucosal bleeding in end-stage chronic heart failure patients who require a left ventricular assist device (LVAD) 
  • In May 2020 Mesoblast, Inc. completed a trial which was initiated in February 2014, the trial titled “Double-blind, Randomized, Sham procedure-controlled, parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells(Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1” 

 

Heart Failure Pipeline Therapeutics Assessment

  • Heart Failure Assessment by Product Type
  • Heart Failure By Stage and Product Type
  • Heart Failure Assessment by Route of Administration
  • Heart Failure By Stage and Route of Administration
  • Heart Failure Assessment by Molecule Type
  • Heart Failure by Stage and Molecule Type 

 

DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:

  • GSK3884464: GlaxoSmithKline
  • LY 3461767: Eli Lilly and Company
  • JK07: Salubris Biotherapeutics
  • NAN-101: Asklepios Biopharmaceutical
  • HS-001: Heartseed Inc.
  • SRD-001: Sardocor Corp.
  • hiPSC-CM therapy: Help Therapeutics
  • Mavacamten: Bristol Myers Squibb
  • HU 6: Rivus Pharmaceuticals
  • PL 3994: Palatin Technologies
  • AZD9977: AstraZeneca
  • Rexlemestrocel-L: Mesoblast
  • Finerenone: Bayer
  • Tirzepatide: Eli Lilly and Company 

 

Heart Failure Pipeline Analysis:

The Heart Failure pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Heart Failure treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
  • Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies

 

Heart Failure Pipeline Market Drivers

  • Biomarkers helps in understanding the complexity of heart failure
  • Recent advancements in research and development
  • Rising geriatric population

 

Heart Failure Pipeline Market Barriers

  • Lack of therapies for HFpEF and acute heart failure
  • High annual cost
  • Long time duration to measure the Clinical trial endpoints

 

Get a Free Sample PDF Report to know more about Heart Failure Pipeline Assessment

 

Scope of Heart Failure Pipeline Drug Insight    

  • Coverage: Global
  • Key Heart Failure Companies: GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Asklepios Biopharmaceutical, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others
  • Key Heart Failure Therapies: GSK3884464, LY 3461767, JK07, NAN-101, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others
  • Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
  • Heart Failure Market Dynamics:  Heart Failure market drivers and Heart Failure market barriers 

 

Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials

 

Table of Contents

1

Heart Failure Report Introduction

2

Heart Failure Executive Summary

3

Heart Failure Overview

4

Heart Failure- Analytical Perspective In-depth Commercial Assessment

5

Heart Failure Pipeline Therapeutics

6

Heart Failure Late Stage Products (Phase II/III)

7

Heart Failure Mid Stage Products (Phase II)

8

Heart Failure Early Stage Products (Phase I)

9

Heart Failure Preclinical Stage Products

10

Heart Failure Therapeutics Assessment

11

Heart Failure Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Heart Failure Key Companies

14

Heart Failure Key Products

15

Heart Failure Unmet Needs

16 

Heart Failure Market Drivers and Barriers

17

Heart Failure Future Perspectives and Conclusion

18

Heart Failure Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Heart Failure drugs and therapies

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market

  Categories: